4XT2

Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains in complex with a tetrazole-containing antagonist

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free: 0.192 
  • R-Value Work: 0.159 
  • R-Value Observed: 0.161 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history. 


Literature

Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2.

Scheuermann, T.H., Stroud, D., Sleet, C.E., Bayeh, L., Shokri, C., Wang, H., Caldwell, C.G., Longgood, J., MacMillan, J.B., Bruick, R.K., Gardner, K.H., Tambar, U.K.

(2015) J Med Chem 58: 5930-5941

  • DOI: 10.1021/acs.jmedchem.5b00529
  • Primary Citation of Related Structures:  
    4XT2

  • PubMed Abstract: 

    • Hypoxia inducible factor (HIF) transcription factors reside at the center of signaling pathways used by mammalian cells to sense and respond to low oxygen levels. While essential to maintain oxygen homeostasis, misregulation of HIF protein activity correlates with tumor development and metastasis ...

    Hypoxia inducible factor (HIF) transcription factors reside at the center of signaling pathways used by mammalian cells to sense and respond to low oxygen levels. While essential to maintain oxygen homeostasis, misregulation of HIF protein activity correlates with tumor development and metastasis. To provide artificial routes to target misregulated HIF activity, we identified small molecule antagonists of the HIF-2 transcription factor that bind an internal cavity within the C-terminal PAS domain of the HIF-2α subunit. Here we describe a new class of chiral small molecule ligands that provide the highest affinity binding, the most effective, isoform-selective inhibition of HIF-2 in cells, and trigger the largest protein conformation changes reported to date. The current results further illuminate the molecular mechanism of HIF-2 antagonism and suggest additional routes to develop higher affinity and potency HIF-2 antagonists.

    Organizational Affiliation: 

    ‡Department of Biochemistry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, United States.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Aryl hydrocarbon receptor nuclear translocatorA [auth B], B [auth D]121Homo sapiensMutation(s): 1 
Gene Names: ARNT, BHLHE2
Find proteins for P27540 (Homo sapiens)
Explore P27540 
Go to UniProtKB:  P27540
NIH Common Fund Data Resources
PHAROS:  P27540
GTEx:  ENSG00000143437
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Endothelial PAS domain-containing protein 1C [auth A], D [auth C]117Homo sapiensMutation(s): 1 
Gene Names: EPAS1, BHLHE73, HIF2A, MOP2, PASD2
Find proteins for Q99814 (Homo sapiens)
Explore Q99814 
Go to UniProtKB:  Q99814
NIH Common Fund Data Resources
PHAROS:  Q99814
GTEx:  ENSG00000116016
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
43L
Query on 43L
Download Ideal Coordinates CCD File 
 E [auth A], F [auth C](5S,7R)-5,7-bis(3-bromophenyl)-4,5,6,7-tetrahydrotetrazolo[1,5-a]pyrimidine
C16 H13 Br2 N5
JHRYBPMSBXHLJL-LSDHHAIUSA-N		 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
43LIC50:  112   nM  BindingDB
43LIC50:  30000   nM  BindingDB
43LKd:  63   nM  BindingDB
43LKd:  70   nM  BindingDB
43LKd:  63   nM  Binding MOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.70 Å
  • R-Value Free: 0.192 
  • R-Value Work: 0.159 
  • R-Value Observed: 0.161 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 74.253α = 90
b = 84.39β = 104.39
c = 82.784γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History & Funding Information

Deposition Data

Funding OrganizationLocationGrant Number
Cancer Prevention and Research Institute of Texas (CPRIT)United StatesRP130513
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesP01 CA95471
Cancer Prevention and Research Institute of Texas (CPRIT)United StatesRP100846

Revision History  (Full details and data files)

  • Version 1.0: 2015-12-09
    Type: Initial release
  • Version 1.1: 2015-12-23
    Changes: Refinement description
  • Version 1.2: 2017-09-06
    Changes: Advisory, Author supporting evidence, Derived calculations
  • Version 1.3: 2019-12-04
    Changes: Author supporting evidence